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S U M M A R Y
Objectives: The rapid diagnosis of bacteremia is crucial for patient management including the choice of
antimicrobial therapy, especially in cases of hematological disease, because neutropenia occurs
frequently during antineoplastic chemotherapy or disease progression. We describe a rapid detection
and identiﬁcation system that uses universal PCR primers to amplify a variable region of bacterial 16S
ribosomal DNA (rDNA), followed by DNA microarray hybridization.
Methods: Probes for 72 microorganisms including most causal clinical pathogens were spotted onto a
microarray plate. The DNA microarray and conventional methods of identiﬁcation were applied to 335
cultures from patients with hematological diseases.
Results: Forty-one samples (12.2%) tested positive by conventional blood culture test in a few days,
while 40 cases (11.9%) were identiﬁed by the new method within 24 h. The sensitivity and speciﬁcity of
this new method were 93% and 99%, respectively, compared with conventional blood culture testing.
Conclusions: PCR combined with a DNA microarray is useful for the management of febrile patients with
hematological diseases.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Blood culture testing is the gold standard for the assessment of
infectious disease. The isolation of bacteria from blood cultures is
usually indicative of a serious invasive infection requiring urgent
antimicrobial therapy. Organisms differ in antimicrobial suscepti-
bility, and successful treatment is dependent on the prompt
administration of the correct drugs. However, it takes a long time
to detect microorganisms. If a culture blot tests positive, some
estimation of bacterial identity can be obtained by Gram staining,
but a deﬁnitive identiﬁcation and assessment of antibiotic
susceptibility requires 3–5 days for most organisms and even
longer for fastidious organisms.1,2
Antineoplastic chemotherapy for hematological malignan-
cies is quite intensive and can cause severe neutropenia
leading to serious infection.3–5 Fever without the appearance
of infectious focal signs is often seen in patients with
neutropenia after antineoplastic chemotherapy. The Infec-
tious Diseases Society of America (IDSA) has deﬁned such
fever as febrile neutropenia.6 However, the causative* Corresponding author. Tel.: +81 776 61 3111; fax: +81 776 61 8109.
E-mail address: hiwasaki@u-fukui.ac.jp (H. Iwasaki).
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is sometimes rapidly progressive with a fatal outcome. There
is a need to identify the causative microorganisms  more
rapidly and with higher sensitivity, especially in cases of
febrile neutropenia.7
Molecular diagnostic methods, such as the multiplex PCR and
real-time PCR, have considerably enhanced the speed and
sensitivity of detection and identiﬁcation of microbial pathogens
in blood samples.8–12 PCR technology has simpliﬁed and acceler-
ated the process of amplifying nucleic acids in vitro, and many
primer sets have been developed to detect species-speciﬁc
sequences in simple PCRs.13–16 However, the single use of
species-speciﬁc primers is impractical for the routine analysis of
clinical samples that may contain several pathogens. 16S
ribosomal DNA (rDNA) can be used to facilitate the diagnosis of
infectious diseases of bacterial origin.17 The 16S rDNA contains
regions that are highly conserved in most bacteria.18
We ampliﬁed a variable region of bacterial 16S rDNA by PCR,
and then used DNA microarray hybridization to detect micro-
organisms rapidly. The microarray covered 72 microorganisms
often identiﬁed by blood culture. We believe the PCR–microarray
method to be a more effective, sensitive, and rapid means of
detecting pathologic microorganisms in clinical practice than
conventional blood culture testing.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Collection of clinical samples
We conducted a study from May 2004 through February 2007 in
the hematology ward at the University of Fukui Hospital, a 600-bed
tertiary referral hospital. Some 335 blood specimens from 99
patients with febrile hematological diseases were used in this
study. Approximately 51% (172/335) were from cases of febrile
neutropenia.
2.2. Sample collection and conventional microbiological identiﬁcation
of clinical isolates and processing
Blood culture tests were performed in our hospital laboratory
using the automated system BacT/ALERT 3D (bioMe´rieux,
France). Up to 10 ml of blood was placed in anaerobic and aerobic
blood culture bottles (BacT/ALERT Culture Media, bioMe´rieux,
France), which were incubated in the machine and monitored
continuously for evidence of bacterial growth. If growth was
identiﬁed, the bottle was removed from the incubator, and a
sample was taken for Gram staining and subcultured on agar
plates. DNA assays were performed in the Mitsubishi Chemical
Medience Corporation (MBC) laboratory. Culture bottles were
sent to the laboratory, at which not only the DNA assay but also
culture tests were performed. Blood culture tests were performed
in the MBC laboratory using a different automated system
(BACTEC 9240, Becton Dickinson), so we took one more set
simultaneously in another blood culture bottle (BACTEC 92F, 93F,
Becton Dickinson, Franklin Lakes, NJ) to send to that laboratory for
two-thirds of samples (n = 214). However, in a third of samples
(n = 121), clinicians took only one type of culture bottle (BacT/
ALERT Culture Media) for testing in our hospital laboratory. In
these cases, we sent the bottles to the MBC laboratory after the
blood culture test had been carried out in our laboratory. The
difference in these culture bottles is the presence or absence of
resin that inhibits antibiotic activity. The BacT/ALERT Culture
Media culture bottles do not contain resin, but the BACTEC 92F,
93F (Becton Dickinson, Franklin Lakes, NJ) culture bottles do.
Microorganisms were identiﬁed by conventional methods.Table 1
Seventy-two microorganisms identiﬁed by the microarray
Staphylococcus species Other Gram-positive bacteria Non
Staphylococcus aureus Aerococcus viridans Pseu
Staphylococcus epidermidis Gemella morbillorum Bur
Staphylococcus haemolyticus Micrococcus luteus Sten
Staphylococcus hominis Bacillus cereus Acin
Staphylococcus intermedius Bacillus subtilis Alca
Staphylococcus saprophyticus Corynebacterium jeikeium Alca
Staphylococcus warneri Corynebacterium aquaticum Chr
Listeria monocytogenes Chr
Com
Streptococcus species Enterobacteriaceae Oth
Streptococcus pneumoniae Escherichia coli Hae
Streptococcus pyogenes Klebsiella pneumoniae Mor
Streptococcus agalactiae Klebsiella oxytoca Neis
Streptococcus bovis Serratia marcescens Aero
Streptococcus canis Salmonella Typhi, Paratyphi A Eike
Streptococcus equisimilis Enterobacter cloacae Acti
Streptococcus anginosus Enterobacter aerogenes Legi
Streptococcus constellatus Pantoea agglomerans 
Streptococcus intermedius Citrobacter freundii 
Streptococcus mitis Citrobacter koseri
Streptococcus oralis Morganella morganii
Streptococcus sanguinis Proteus mirabilis
Providencia stuartiiAerobic and anaerobic blood culture bottles were incubated for
3–15 days and the results were reported.
2.3. Extraction of bacterial DNA from pure bacterial cultures
The DNA assay was performed without any knowledge of the
patient’s details or the initial Gram staining results. DNA was
extracted from all culture bottles in a class II safety cabinet using
the following protocol. A 2-ml aliquot from a culture incubated for
7 h was mixed with 6 ml of lysis buffer (155 mM NH4Cl, 10 mM
KHCO3, 100 mM ethylenediaminetetraacetic acid disodium salt
(EDTA2Na) pH7.4) and put on ice for 10 min. Following
centrifugation at 1600 g for 10 min at 4 8C, the pellet was
resuspended in 1 ml of lysis buffer. Next, it was centrifuged at
20 000 g for 5 min and the pellet was re-suspended in cell
suspension solution (Gentra Systems, Minneapolis, MN) contain-
ing 10 ml of 10% Tween 20 (Sigma, St. Louis, MO), 4 U/ml lytic
enzyme (Gentra Systems, Minneapolis, MN), and 100 U/ml
achromopeptidase (Wako, Osaka, Japan), and incubated at 37 8C
for 30 min. The temperature was then raised to 70 8C for 10 min
after 10 ml of protease K (600 mU/ml) was added. Next, 200 ml of
phenol:chloroform (1:1) was added and the culture was
centrifuged at 20 000 g for 5 min at 25 8C; the supernatant was
then used for the 16S PCR procedure below. There was no PCR
inhibitor in one culture bottle (BacT/ALERT Culture Media), but
the other culture bottle (BACTEC) contained polyanetholesulfo-
nate, which inhibits PCR. We used benzyl alcohol to get rid of the
polyanetholesulfonate when we extracted DNA after the above
procedure for this particular culture bottle (BACTEC).
2.4. PCR ampliﬁcation of bacterial 16S rDNA
The bacterial 16S rDNA was ampliﬁed from genomic DNA
using universal PCR primers: 50-AGAGTTTGATCCTGGCTCAG-30
(forward) and 50-GTATTACCGCGGCTGCTGG-30 (reverse), corre-
sponding to positions 8–27 and 517–535, respectively, of the
Escherichia coli 16S rDNA gene. The reaction proﬁle was 35
cycles of denaturation at 94 8C for 30 s, annealing at 55 8C for 60
s, and extension at 72 8C for 30 s, with the ﬁnal extension step
at 72 8C for 3 min (Gene Amp PCR system 9600; Perkin-Elmer-glucose fermentative Gram-negative rod Anaerobes
domonas aeruginosa Bacteroides fragilis
kholderia cepacia Prevotella melaninogenica
otrophomonas maltophilia Fusobacterium nucleatum
etobacter calcoaceticus Veillonella parvula
ligenes faecalis Clostridium perfringens
ligenes xylosoxidans Eubacterium lentum
yseobacterium indologenes Propionibacterium acnes
yseobacterium meningosepticum Lactobacillus acidophilus
amonas acidovorans Peptostreptococcus magnus
er Gram-negative bacteria Enterococcus species
mophilus inﬂuenzae Enterococcus faecalis
axella (Branhamella) catarrhalis Enterococcus faecium
seria meningitidis Enterococcus avium
monas hydrophila Enterococcus casseliﬂavus
nella corrodens Enterococcus gallinarum
nobacillus actinomycetemcomitans
onella pneumophila Mycobacteria
Mycobacterium gordonae
Mycobacterium kansasii
Figure 1. Overview of the conventional culture test and microarray method.
Table 2
Distribution of hematological diseases among 335 infectious episodes in 99 patients
Episodes (%) Patients
Acute myeloid leukemia (AML) 152 (45.4) 33
Non-Hodgkin lymphoma (NHL) 105 (31.3) 34
Acute lymphoid leukemia (ALL) 38 (11.3) 8
Multiple myeloma (MM) 17 (5.1) 10
Myelodysplastic syndrome (MDS) 12 (3.6) 5
Aplastic anemia (AA) 4 (1.2) 2
Chronic myeloid leukemia (CML) 2 (0.6) 2
Essential thrombocytosis (ET) 2 (0.6) 2
Hodgkin lymphoma (HL) 1 (0.3) 1
Chronic myelomonocytic leukemia (CMMoL) 1 (0.3) 1
Primary myeloﬁbrosis (MF) 1 (0.3) 1
Total 335 99
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size by agarose gel electrophoresis. We established a threshold
to decrease the false-positive rate using a quantitative
competitive PCR (QC-PCR). We designed PCR products as a
competitor using primers that target the 16S rRNA of
Staphylococcus aureus, and inserted the products into the
plasmid without the V1, V2, and V3 regions to avoid
hybridization to the DNA microarray. We used the minimum
amount of primers (20–30 copies/reaction tube) for the
competitor. The competitor was used for two purposes. The
ﬁrst was to evaluate if the genes could be ampliﬁed by PCR. The
second was to cancel the nonspeciﬁc ampliﬁcation by PCR. The
results were determined to be negative when only the
competitor was ampliﬁed, as positive if 500 bp genes were
ampliﬁed more than the competitor, and as PCR failure if no
genes were ampliﬁed.
2.5. Preparation of the DNA microarray chip
The variability of the 16S rDNA sequence was initially
determined using public databases (GenBank), and we sequenced
PCR products from selected clinical isolates in our collection. The
PCR products of 16S rDNA were sequenced with an automated
sequencer (PE Applied Biosystems, Foster City, CA), and consensus
regions of each species were identiﬁed. The consensus regions
were aligned using Clustal W,19 and the 500-bp sequences at the 50
end including the variable regions (V1, V2, and V3) were identiﬁed.
The theoretical speciﬁcity of all the primer and probe sequences
was analyzed using the BLAST NCBI program.20 The oligoprobe
(50 bp), corresponding to the variable regions, and PCR products
that were ampliﬁed by the 27f and r1L primers were spotted onto
plastic slides using an instrument for making microarrays (SPBIO;
Hitachi Soft Engineering, Yokohama, Japan). The sequences of the
72 probes are already listed in another article on osteoarticular
infections.21 This probe identiﬁes the conﬁrmed sequences of each
of the 72 microorganisms, which are almost exclusively pathogens
causing clinical disease (Table 1). This probe was developed
previously (patent No. WO2003/106676). One can detect 93% of
pathogens in blood cultures by the frequency of the top 28
microorganisms.222.6. Labeled PCR products and DNA hybridization
The PCR products from samples were labeled with Cy5 primers:
50-Cy5-CTCACCCGT-30 (Cy5 120R), 50-Cy5-TGCCTCCCG-30 (Cy5
350R), and 50-Cy5-TGCTGGCAC-30 (Cy5 520R). The labeling reaction
was carried out for 20 cycles (37 8C for 5 s and 94 8C for 5 s) using a
thermal cycler. An aliquot of 45 ml of the PCR product was used for
hybridization in 200 ml of solution containing 40% formaldehyde,
5  saline sodium citrate (SSC), and 0.2% sodium dodecyl sulfate
(SDS). The solution was heated for 2 min at 96 8C, applied to the
microarray equipped with a 40  22  0.25 mm plastic chamber
(Invitrogen, Carlsbad, CA), and incubated at 55 8C for 1 h. The
microarray was then rinsed with 2  SSC, washed with 2  SSC,
exposed to 0.2% SDS, exposed to 0.2% SDS at 50 8C for 5 min, and
ﬁnally rinsed with 0.05  SSC.
2.7. Fluorescence scanning and automated data analysis
The microarray was scanned using a ScanArray 4000 (Axon
Instruments, Union City, CA) to determine the amount of Cy5-
labeled PCR product. Fluorescence intensity was calculated with
DNASIS Array software (Hitachi Software Engineering, Yokohama,
Japan). The data were not normalized to carry out the test, because
we do not need to make comparisons with other DNA microarray
tips. If we just detected one ﬂuorescent signal that would mean the
Table 3
Comparison of results obtained by DNA microarray and by conventional culture for
335 clinical samples
DNA microarray Blood culturing No. of specimens Ratio (%)
Positive Positive 38 11.3
Positive Negative 2 0.6
Negative Positive 3 0.9
Negative Negative 292 87.2
Total 335 100
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
92.7 99.3 95.0 99.0
Sensitivity and speciﬁcity of the DNA microarray method compared with
conventional blood culture tests. PPV, positive predictive value; NPV, negative
predictive value.
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DNA microarray tip was a 50-mer, so that probe can hybridize to
not only full-matched products but also 3-basis mismatched DNA
products; however 4-basis mismatched products cannot be
hybridized. We listed bacteria in order of high ﬂuorescence
intensity by permutation of V1, V2, and V3 spot. We identiﬁed
bacteria in the top rank of the list.
2.8. Statistical analysis
Differences between groups were examined for statistical
signiﬁcance using the Chi-square test. A p-value of <0.05 was
considered to represent a statistically signiﬁcant difference.
3. Results
We compared the sensitivity and speciﬁcity of the DNA
microarray method with those of culture tests on 335 blood
specimens from 99 patients with hematological diseases who had
a febrile illness (Figure 1, Table 2).
The results are shown in Table 3. Forty-one samples (12.2%)
tested positive after a few days of culture, while 40 cases (11.9%)
were identiﬁed by the new method within 24 h. The positive rate
for PCR followed by the microarray method was not signiﬁcantly
higher than that for blood culture. The sensitivity and speciﬁcity of
the microarray method compared with conventional blood culture
testing were 92.7% and 99.3%, respectively.Figure 2. Comparison of results obtained by the DNA microarray method and convention
not. Positive rates were higher for the samples without antibiotics (n = 42) than those w
and the DNA microarray method. Positive rates were higher with bottles containing res
withantibiotics, but there was no difference between the blood culture test and DNA mForty-three samples were identiﬁed as positive by blood culture
or the DNA microarray method, or both. For 13 (30%) specimens,
there was perfect agreement between the two methods. For 25
(58%) specimens, there was partial agreement, for example at the
genus but not species level. For 5 (12%) specimens, there was no
agreement: two of ﬁve were detected only by the DNA microarray
method and another two of ﬁve only by blood culture. One of ﬁve
specimens was negative at ﬁrst, but Bacillus cereus was detected by
long-term culture, while only uncertain PCR products obtained
with the DNA microarray method were positive (Supplementary
Material, Appendix 1).
Regarding antimicrobial chemotherapy, 42 samples were free
of antibiotics, but 293 were from patients who had been
administered antibiotics before the sampling. We analyzed
positive rates separately for those with and without antibiotics.
Positive rates were higher without antibiotics, but the difference
was not signiﬁcant. Positive rates were similar among the methods
with and without antibiotics (DNA microarray vs. blood culture
with antibiotics: 14.3% vs. 14.3%, without antibiotics: 11.7% vs.
12.0%) (Figure 2). In this study, we used two types of culture bottle.
Bottles containing resin that inhibited antibiotic activity were used
for both methods in 92 samples, and bottles not containing resin in
104 samples, under the conditions with antibiotics. In the other
cases, both types of bottle were used (42 samples without
antibiotics, 97 with antibiotics). Positive rates were higher with
than without resin (DNA microarray positive cases with resin
bottles vs. those with resin-free bottles: 18.5% vs. 7.7%, Chi-
square = 5.1, p < 0.05; blood culture: 18.5% vs. 8.7%, Chi-
square = 4.1, p < 0.05), but rates for both the DNA microarray
method and the conventional blood culture testing were similar
under the same conditions (DNA microarray vs. blood culture with
resin: 18.5% vs. 18.5%, without resin: 7.7% vs. 8.7%) (Figure 2).
4. Discussion
The gold standard for detecting bacteremia is blood culture.
However, the positive rate is low and the turnaround time is often
too long.23 Positive cultures are obtained only 12.2% of the time
(Table 3) and the turnaround time is usually 3–15 days (median 4
days) (Supplementary Material, Appendix 2). Consequently,
considerable effort has been devoted to the development of rapid,
sensitive, and speciﬁc assays for the detection of these organ-
isms.24–26 PCR is one of the most important molecular toolsal blood culture test with or without antibiotics and with antibiotics using resin or
ith antibiotics (n = 293), but there was no difference between the blood culture test
in (n = 92) than those not containing resin (n = 104) under conditions of treatment
icroarray method.
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PCR-based assays, real-time PCR is well established in virology, and
has recently also become established in bacteriology. In addition,
microarrays can be coupled with PCR to enhance the detection and
identiﬁcation of products.1,30,31 Recently, Tissari et al. compared
the use of PCR followed by a DNA microarray with blood cultures in
cases of positive culture.32 They found the PCR–DNA microarray
method to have good sensitivity, speciﬁcity, and rapidity, but the
DNA microarray is still not common in microbial diagnostics. We
have investigated a PCR method for the identiﬁcation of organisms
causing bacteremia associated with hematological diseases.
Universal primers were used to amplify a conserved region of
bacterial 16S rDNA, and the PCR products were characterized by
reverse hybridization to the DNA microarray. The use of a single
protocol for all bacterial species is essential for testing blood
cultures, as a bacterial diagnosis is usually uncertain at ﬁrst. We
used primers capable of producing PCR products from common
organisms causing bacteremia and then used a protocol for direct
application to blood culture broths. The use of relatively long,
moderately degenerate universal primers with a high annealing
temperature allowed the 16S rDNA to be targeted while avoiding
nonspeciﬁc ampliﬁcation.
The sensitivity of the PCR method is so high that some
microorganisms could be detected in all blood samples. It is
important to reduce the risk of contamination from not only the
environment, but also PCR materials. We need to set a cut-off level
to distinguish true pathogens from false-positives due to
contamination. Our system used competitive PCR to avoid false-
positive results. Consequently, the positive rate was the same as for
conventional blood tests. If contamination can be avoided in the
PCR step, the cut-off level can be decreased, so the positive rate will
increase.
In this study, 214 of 335 specimens were tested using these two
methods simultaneously. The remaining 121 specimens were
subjected to culture tests ﬁrst and then to the DNA microarray
method. The different conditions did not affect the positive rate
between the DNA microarray method and blood culture test (data
not shown).
This new DNA microarray method has the potential to diagnose
bacteremia rapidly and detect pathogens at the same rate as the
conventional blood culture method.
Regarding the possibility of improving its sensitivity and
speciﬁcity, this method could be the most useful for pathogens
reported to be life-threatening to patients with hematological
diseases. One such pathogen is Bacillus cereus, which causes
fulminant sepsis and needs to be treated within 24 h.33–35 It is
difﬁcult to detect the pathogen within 24 h using conventional
testing. Gram staining can provide information about microorgan-
isms rapidly, but cannot detect the bacterial species. We
experienced several cases in which the DNA microarray method
could identify this microorganism rapidly at the species level.
In this study, we used two types of culture bottle. The bottles
containing resin that inhibits antibiotic activity showed much
higher positive rates than those without resin.36,37 However, there
were no differences between the DNA microarray method and
blood culture test under the same conditions.
One study applied real-time PCR to hematological malignan-
cies, but this system covered relatively few microorganisms.38 The
present investigation is the ﬁrst to use a DNA microarray based on
16S rDNA covering clinically common microorganisms related to
hematological diseases.
One shortcoming of the PCR–microarray method is that it
cannot yet accurately assess sensitivity to antibiotics. Genes such
as mecA conferring resistance to methicillin, bla for resistance to
third-generation cephalosporins, mutated gyrA/B providing resis-
tance to ﬂuoroquinolones, and acrA/B and mexA/B encoding efﬂuxpumps conferring resistance to a wide range of antibiotics have
already been detected by the DNA microarray method,32,39,40 but
many mechanisms of drug resistance, like the production of
enzymes that degrade antibiotics (beta-lactamases), changes to
the active sites of antibiotics in bacteria, and drug extraction
pumps of bacterial membranes, remain to be elucidated. In the
future, if we can cover most drug resistance genes, the DNA
microarray method will become a gold standard. Another
shortcoming of the DNA microarray method is the cost of $200
per test; the blood culture test costs $20 per test. However, if the
DNA microarray method became a more common test this would
result in signiﬁcantly reduced costs.
In conclusion, the DNA microarray is a promising tool for the
rapid detection of microorganisms in febrile patients with
hematological diseases.
Further studies with more patients are needed to conﬁrm the
present ﬁndings.
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